Yahoo Αναζήτηση Διαδυκτίου

Αποτελέσματα Αναζήτησης

  1. 1 Ιαν 2021 · In acute asthma exacerbations the additional administration of oral montelukast results in a significantly higher PEF the morning after admission than that achievable with current standard treatment. Clinical trial number NCT01011452.

  2. ICSs are generally superior to montelukasts for asthma management. However, montelukast has a place in the treatment of young children with viral-triggered wheezing diseases, exercise-induced asthma, and in children whose parents are steroid-phobic and find ICS unacceptable.

  3. In acute asthma, montelukast could statistically improve peak expiratory flow percent predicted (p = 0.008) and reduce systemic corticosteroid intake (p = 0.005). Montelukast had low risk in hoarseness and insomnia.

  4. The role of montelukast in improving QOL of adult patients with mild to moderate persistent asthma is quite beneficial. It improves patient quality of life. It has the ease of once daily oral administration and also eradicates side effects associated with long-term adherence to steroids.

  5. The goal of asthma exacerbation treatment is to relieve symptoms and return patients to their best lung function. Treatment includes. Inhaled bronchodilators (beta-2 agonists and anticholinergics) Usually systemic corticosteroids. (See also Asthma and Drug Treatment of Asthma.)

  6. Oral montelukast in acute asthma exacerbations: a randomised, double-blind, placebo-controlled trial. Crichton F Ramsay 1, Darcy Pearson 1, Sue Mildenhall 1, Andrew M Wilson 1, 2. Department of Respiratory Medicine, Norfolk & Norwich University Hospital, Norwich, UK.

  7. Effective and efficient treatment of acute asthma in the emergency department requires prompt recognition of the signs and symptoms that indicate a potentially fatal asthma attack (Table 2).

  1. Γίνεται επίσης αναζήτηση για